FDA’s final CMC guidance sets expectations for manufacturing and quality for human gene therapy INDs. This article reviews existing analytical applications, focusing on viral vector characterization of impurities.
Peter Wunderli
Advertisement
Articles by Peter Wunderli
Advertisement
Latest Updated Articles
Viral Vector API Characterization of Product-Related ImpuritiesOctober 15th 2020
Advertisement
Advertisement
Trending on BioPharm International
1
Alvotech, Advanz Submit First Eylea 8 mg Biosimilar Bid
2
Lilly's Mirikizumab (Omvoh) Hits New IBD Remission Goals
3
Shift to In Vivo CAR T Will Reshape Facility Design, Says Arcadis’ Emily Heffernan
4
The BioPharm Brief: New Approvals, Biosimilar Competition, and Deeper Remission
5